Aquarius Surgical Technologies (ASTI) AI Stock Analysis

• Market Cap: $275.99K
• Dividend Yield: N/A
• Average Volume (3M): 7.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: -52.36%
• EPS Growth: 70.49%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 27,599,173
• 10 Day Avg. Volume: 11,575
• 30 Day Avg. Volume: 7,525
• PEG Ratio: -0.01
• Price to Book (P/B): -0.10
• Price to Sales (P/S): 6.05
• P/FCF Ratio: -1.44
• Enterprise Value/Market Cap: 4.39
• Enterprise Value/Revenue: 11.02
• Enterprise Value/Gross Profit: 24.83
• Enterprise Value/Ebitda: -2.21
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: C$0.00 ▼(-100.00% Downside)

Aquarius Surgical Technologies receives a low overall stock score of 37 due to significant financial challenges, bearish technical indicators, and concerning valuation metrics. The company's declining revenues, persistent losses, high leverage, and liquidity issues are major concerns. Additionally, the technical analysis indicates a strong downtrend and oversold conditions, while the negative P/E ratio reflects a lack of profitability.

Aquarius Surgical Technologies Business Overview & Revenue Model

Company Description

Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., develops, sells, distributes, and markets technologies for use in surgical and other environments in Canada and the United States. It offers medical laser solutions across multiple medical disciplines, including urology, gynecology, ophthalmology, thoracic, ENT, cardiovascular, and neurosurgery. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.

How the Company Makes Money

ASTI generates revenue primarily through the sale of its surgical instruments and technologies to hospitals, surgical centers, and healthcare providers. Key revenue streams include direct sales of its robotic-assisted surgical systems, which often involve significant upfront costs, as well as recurring revenue from the sale of disposable components and accessories necessary for the operation of these systems. Additionally, ASTI may engage in partnerships with other medical technology companies and healthcare organizations to co-develop products or expand its market reach, further enhancing its revenue potential. Licensing agreements for proprietary technologies and participation in training and support programs for healthcare professionals also contribute to the company's earnings.

Aquarius Surgical Technologies Financial Statement Overview

Summary

Aquarius Surgical Technologies is facing significant financial challenges. The income statement shows declining revenues and persistent losses, the balance sheet reflects high leverage and negative equity, and the cash flow statement indicates liquidity issues with negative cash flows. The company needs to address its operational inefficiencies and improve its financial stability.

Income Statement

Aquarius Surgical Technologies has experienced declining revenues with a negative revenue growth rate of -17.1% in the most recent year. The company also shows negative profit margins, with a net profit margin of -12.8%, indicating significant losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, the income statement reveals financial struggles with declining revenues and persistent losses.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, resulting in a negative debt-to-equity ratio. This indicates that liabilities exceed assets, posing a risk to financial stability. The return on equity is positive, but this is due to the negative equity base rather than profitability. Overall, the balance sheet reflects high leverage and financial instability.

Cash Flow

The cash flow statement shows negative operating and free cash flows, indicating cash outflows from operations. The free cash flow to net income ratio is 1.0, suggesting that cash flows are aligned with net losses. However, the negative operating cash flow coverage ratio highlights challenges in covering operational expenses. Overall, the cash flow statement reflects liquidity challenges and insufficient cash generation.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	110.02K	91.20K	205.25K	203.73K	327.66K	583.44K
Gross Profit	48.83K	47.31K	132.85K	81.91K	130.30K	216.59K
EBITDA	-548.63K	-832.81K	-456.62K	-496.83K	-611.35K	-1.30M
Net Income	-904.61K	-1.17M	-757.66K	-723.44K	-859.20K	-1.81M
Balance Sheet
Total Assets	473.42K	1.95M	574.44K	680.14K	894.98K	946.13K
Cash, Cash Equivalents and Short-Term Investments	5.29K	7.56K	107.38K	122.02K	158.19K	145.97K
Total Debt	4.53M	6.47M	4.04M	3.51M	3.24M	2.93M
Total Liabilities	5.76M	7.72M	5.18M	4.53M	4.11M	3.34M
Stockholders Equity	-5.29M	-5.77M	-4.61M	-3.85M	-3.21M	-2.39M
Cash Flow
Free Cash Flow	-393.52K	-383.29K	-256.92K	38.82K	-117.38K	-509.00K
Operating Cash Flow	-387.55K	-383.29K	-252.56K	38.82K	-112.16K	-450.52K
Investing Cash Flow	0.00	-1.80M	-4.36K	0.00	-5.22K	-100.00K
Financing Cash Flow	254.09K	2.08M	242.29K	-75.00K	129.59K	591.30K

Aquarius Surgical Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASTI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 21.30 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ASTI.

Aquarius Surgical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PINK	48 Neutral	C$26.73M	-0.83	-361.49%	―	219.12%	-15.92%
THRM	45 Neutral	C$6.25M	-1.66	―	―	57.50%	16.20%
ASG	44 Neutral	C$22.64M	-14.15	-28.62%	―	17.61%	-19.19%
TLT	40 Underperform	C$48.84M	-10.86	-205.86%	―	16.00%	9.79%
ASTI	37 Underperform	$275.99K	―	16.76%	―	-52.36%	70.49%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%